Abstract 278P
Background
Radiotherapy is an effective treatment option for local control of prostate cancer, but its role in the treatment of oligometastatic prostate cancer (omPCa) remains unclear. This study aimed to investigate the potential survival benefit of full-coverage radiotherapy in patients with omPCa.
Methods
A retrospective analysis was conducted on patients with omPCa who received full-coverage radiotherapy between July 2012 and June 2022. Full-coverage radiotherapy was defined as radiotherapy to all lesions, including the primary site and metastatic lesions. Overall survival (OS) was the primary endpoint, and biochemical progression-free survival (bPFS) and radiological progression-free survival (rPFS) were the secondary endpoint. The Kaplan-Meier method was used to estimate univariate analysis, and the log-rank test was used to conduct multivariate analysis.
Results
A total of 33 patients, including 31 de novo oligometastatic hormone-sensitive prostate cancer (omHSPC) patients and 2 oligometastatic castration-resistant prostate cancer (omCRPC) patients, were enrolled in the study. The median follow-up was 38.8 months (range: 4.2–70.6 months). The survival rates at 2, 3, and 5 years were 100%, 95.7%, and 81.2%, respectively. The median bPFS was 58.9 months (95% CI: 47.7 - 70.1 months). The median rPFS is 55.3 months (95% CI: 39.9 -70.8 months). According to the univariate analysis, TURP prior to radiotherapy, presence of symptoms related to the lesions, and the pre-radiotherapy status of CRPC were associated with poorer survival. Multivariate analysis showed EBRT synchronized with ADT or chemotherapy (p=0.016), non-CRPC status before radiotherapy(p=0.000), and PSA levels more than 1 ng/ml before radiotherapy ( p=0.014) may be associated with longer rPFS. Both univariate and multivariate studies have demonstrated that the coexistence of lymph node and bone metastases is associated with a higher risk of biochemical recurrence (p=0.02). The occurrence of acute adverse reactions of Grade 3 or higher was not observed.
Conclusions
Full-coverage radiotherapy with an optimistic bPFS and rPFS may improve the OS of patients with oligometastatic prostate cancer. Further prospective studies are warranted to confirm the findings of this retrospective analysis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Department of Radiation Oncology, Shanghai Changhai Hospital, the Naval Medical Universit.
Funding
The First Affiliated Hospital of Navy Medical University “234 Subject Climbing Program” (2019YPT004), the First Affiliated Hospital of Naval Medical University “Youth Development Program”(2021JCQNO3).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
519P - Final results and subgroup analysis of ORIENTAL: A phase IIIB study of durvalumab plus platinum-etoposide in first-line treatment of Chinese patients with extensive-stage small-cell lung cancer (ES-SCLC)
Presenter: Ying Cheng
Session: Poster Display
Resources:
Abstract
520P - Role of atezolizumab in controlling CNS progression in ES-SCLC
Presenter: Yoon Namgung
Session: Poster Display
Resources:
Abstract
521P - Camrelizumab combined with chemotherapy and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory research
Presenter: Yanbin Zhao
Session: Poster Display
Resources:
Abstract
522P - Durvalumab plus etoposide and carboplatin for extensive-stage small cell lung cancer with mild idiopathic interstitial pneumonia
Presenter: Ichiro Nakachi
Session: Poster Display
Resources:
Abstract
523P - Camrelizumab plus apatinib as maintenance treatment in patients with extensive-stage small cell lung cancer who were responding or stable after standard first-line chemotherapy (CAMERA): Results from a single-arm, phase II trial
Presenter: Qi Wang
Session: Poster Display
Resources:
Abstract
524P - Treatment pattern and overall survival by lines of therapy among patients with advanced small cell lung cancer in Taiwan
Presenter: Kelly Huang
Session: Poster Display
Resources:
Abstract
525P - Development of diagnostic prediction score for malignant pleural effusion in lung cancer: MPE-Lung score
Presenter: Chaichana Chantharakhit
Session: Poster Display
Resources:
Abstract
526P - Burden and trends of tracheal, bronchus, and lung (TBL) cancer in Southeast Asia, East Asia, and Oceania from 1990-2019, and its projection of deaths to 2040: A benchmarking analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
527P - Efficacy of intraventricular chemotherapy with pemetrexed for leptomeningeal metastasis from lung adenocarcinoma: A retrospective study
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
528P - Socioeconomic determinants of access to standard-of-care treatments in advanced and metastatic NSCLC in Hong Kong: A territory-wide study
Presenter: Ka Man Cheung
Session: Poster Display
Resources:
Abstract